Patents Assigned to Stealth BioTherapeutics Inc.
-
Publication number: 20240108740Abstract: Disclosed herein are methods and compositions for the treatment, prevention, inhibition, amelioration and/or delay in the onset of diseases, disorders and/or conditions comprising administration of SPN10 or an analogue thereof, alone or in combination with one or more additional active agents (e.g. active pharmaceutical ingredients), wherein SPN10 is the aromatic-cationic peptide, H-L-Trp-L-Arg-L-Trp-L-Lys-NH2, or a pharmaceutically acceptable salt, tautomer, hydrate, and/or solvate thereof.Type: ApplicationFiled: April 5, 2023Publication date: April 4, 2024Applicant: Stealth BioTherapeutics Inc.Inventor: Brian D. Gildea
-
Patent number: 11944662Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: August 11, 2023Date of Patent: April 2, 2024Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Publication number: 20240100119Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.Type: ApplicationFiled: April 28, 2023Publication date: March 28, 2024Applicant: Stealth BioTherapeutics Inc.Inventor: D. Travis Wilson
-
Patent number: 11931397Abstract: The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.Type: GrantFiled: December 5, 2019Date of Patent: March 19, 2024Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: James Carr, Michael Dimatteo, Anthony Abbruscato, Hans Bjornsson
-
Publication number: 20240059735Abstract: The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.Type: ApplicationFiled: April 17, 2023Publication date: February 22, 2024Applicant: Stealth BioTherapeutics Inc.Inventor: D. Travis Wilson
-
Publication number: 20240024408Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: February 8, 2023Publication date: January 25, 2024Applicant: Stealth BioTherapeutics Inc.Inventor: D. Travis Wilson
-
Publication number: 20230405080Abstract: The disclosure generally relates to compounds (i.e. peptidomimetics), compositions (e.g. formulations or medicaments), methods and related uses for treating, preventing, inhibiting, amelioration or delaying the onset of ophthalmic diseases, disorders or conditions in a mammalian subject, such as a human. In some embodiments, the ophthalmic disease, disorder or condition may be associated with deterioration of the integrity of the ellipsoid zone of one or more eyes of the mammalian subject. The methods and uses comprise administering an effective amount of peptidomimetic (alone, as formulated and/or in combination with at least one additional therapeutic agent) to mammalian subjects in need thereof.Type: ApplicationFiled: September 1, 2023Publication date: December 21, 2023Applicant: Stealth BioTherapeutics Inc.Inventors: Dennis Keefe, Martin Redmon, Brian Hotchkiss, Anthony Abbruscato
-
Publication number: 20230381264Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: August 11, 2023Publication date: November 30, 2023Applicant: Stealth BioTherapeutics Inc.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Publication number: 20230346874Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: February 9, 2023Publication date: November 2, 2023Applicant: Stealth BioTherapeutics Inc.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Patent number: 11795196Abstract: Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.Type: GrantFiled: December 14, 2018Date of Patent: October 24, 2023Assignee: Stealth BioTherapeutics Inc.Inventors: Guozhu Zheng, Mark J. Bamberger, Inese Smukste
-
Patent number: 11773136Abstract: Disclosed are various crystalline salt forms of Boc-D-Arg-DMT-Lys(Boc)-Phe-NH2.Type: GrantFiled: April 8, 2021Date of Patent: October 3, 2023Assignee: Stealth BioTherapeutics Inc.Inventor: Scott M. Duncan
-
Patent number: 11771734Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.Type: GrantFiled: July 9, 2021Date of Patent: October 3, 2023Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: D. Travis Wilson, Mark Bamberger
-
Publication number: 20230303506Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).Type: ApplicationFiled: December 23, 2022Publication date: September 28, 2023Applicant: Stealth BioTherapeutics Inc.Inventors: Dennis Keefe, Guozhu Zheng, Pavels Arsenjans
-
Publication number: 20230279051Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: October 11, 2022Publication date: September 7, 2023Applicant: Stealth BioTherapeutics Inc.Inventor: D. Travis Wilson
-
Publication number: 20230256047Abstract: The disclosure provides methods for treating muscular dystrophy (MD), such as Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD) in a mammalian subject. The methods are particularly useful for treating, inhibiting, reducing, ameliorating or delaying the onset of hypertrophic cardiomyopathy, dilated cardiomyopathy, heart failure and/or cardiac fibrosis in subjects diagnosed with, and/or being treated for, MD.The methods comprise administering to the subject an effective amount of a peptide such as H-D-Arg-2,6-Dmt-Lys-PHe-NH2 (a.k.a. elamipretide), or a pharmaceutically acceptable salt, hydrate, solvate and/or tautomer thereof, optionally in combination with at least one other active ingredient (i.e. drug) such a corticosteroid, ACE inhibitor, ARB(s), beta-blocker or drug that increases or corrects the expression of dystrophin in the subject (e.g. Eteplirsen (Exondys 51®), Golodirsen (Vyondys 53™)) or Casimersen (Amondys 45™).Type: ApplicationFiled: June 16, 2021Publication date: August 17, 2023Applicant: STEALTH BIOTHERAPEUTICS INC.Inventors: David BROWN, Jim CARR, Dennis Keefe
-
Publication number: 20230190859Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or seventy of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.Type: ApplicationFiled: June 13, 2022Publication date: June 22, 2023Applicants: Stealth BioTherapeutics Inc., Henry Ford Health SystemsInventors: D. Travis Wilson, Hani N. Sabbah
-
Patent number: 11672841Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.Type: GrantFiled: October 30, 2020Date of Patent: June 13, 2023Assignee: STEALTH BIOTHERAPEUTICS INC.Inventor: D. Travis Wilson
-
Publication number: 20230109564Abstract: The disclosure provides methods of preventing or treating DMD in a mammalian subject, reducing risk factors associated with DMD, and/or reducing the likelihood or severity of DMD. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.Type: ApplicationFiled: May 3, 2022Publication date: April 6, 2023Applicant: Stealth BioTherapeutics Inc.Inventor: D. Travis Wilson
-
Patent number: 11612633Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: GrantFiled: July 2, 2020Date of Patent: March 28, 2023Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
-
Patent number: 11584728Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).Type: GrantFiled: October 2, 2020Date of Patent: February 21, 2023Assignee: STEALTH BIOTHERAPEUTICS INC.Inventors: Dennis Keefe, Guozhu Zheng, Pavels Arsenjans